

This version of the chapter has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature's AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: [http://dx.doi.org/10.1007/978-3-030-64872-5\\_16](http://dx.doi.org/10.1007/978-3-030-64872-5_16)

## **The effects of nutraceuticals and herbal medicine on *Candida Albicans* in oral candidiasis: a comprehensive review**

Fateme Gharibpour<sup>1</sup>, Farinaz Shirban<sup>2</sup>, Mohammad Bagherniya<sup>3</sup>, Mohsen Nosouhian<sup>1</sup>, Thozhukat Sathyapalan<sup>4</sup>, Amirhossein Sahebkar<sup>5</sup>

<sup>1</sup>Post graduate, Dental students, Research Committee, Department of Orthodontics, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>2</sup>Dental Research Center, Department of Orthodontics, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.

<sup>3</sup>Department of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

<sup>4</sup>Hull York Medical School, University of Hull, United Kingdom

<sup>5</sup>Mashhad Institute of Medical Sciences, Mashhad, Iran

### ***Abstract***

*Candida Albicans* is part of the healthy flora in the oral cavity. It can also cause opportunistic infection, which can be deleterious. The most typical type of chronic oral candidiasis is denture stomatitis, and *Candida Albicans* is identified as the most crucial organism in this situation. Due to the development of the resistant form of candida, using conventional drugs can sometimes be ineffective. Herbs and naturally imitative bioactive compounds could become a new source for antimycotic therapy. Several review studies suggest that herbal medicine and natural bioactive compounds have antibacterial, antiviral and antifungal effects. Thus, it is hypothesized that these natural products might have beneficial effects on pathogenic oral fungal flora such as *Candida Albicans*. Although the effects of herbs have been investigated as antifungal agents in several studies, to the best of our knowledge, the effects of these natural products on *Candida Albicans* have not yet been reviewed. Thus, the aim of this study was to review the anti-candida activity (especially *Candida Albicans* in oral candidiasis) of herbal medicines and natural bioactive compounds. It is concluded that, in general, medicinal plants and nutraceuticals such as garlic, green tea, propolis, curcumin, licorice root, cinnamon, resveratrol, ginger, and berberine are useful in the treatment of *Candida Albicans* in oral candidiasis and could be considered as a safe, accessible, and inexpensive management option in an attempt to prevent and treat oral diseases. However, most of the evidence is based on the *in vitro* and animal studies, so more clinical trials are needed.

**Keywords:** *Candida Albicans*; Oral candidiasis; Nutraceuticals; Herbal medicine

## **Abbreviation**

C.albicans, Candida Albicans; CVDs, cardiovascular diseases; EC, epicatechin; EGC, epigallocatechin; ECG, EC gallate; EGCG, EGC gallate; HBD-2, Human beta defensin 2; HC, Heat cure; MW, Microwave; EEP-AP/EEP, extract of propolis; CUR, curcumin; PDT, Photodynamic therapy; PS, photosensitizer; ROS, reaction oxygen species; CHI-CUR, Chitosan-curcuminoid; CHX, chlorhexidine; CHI, vehicle formulation comprising chitosan 0.5% and PEG 400; CUR-NPS, curcumin encapsulated in nanoparticles; NYS4, nystatin four times a day; Nys1, nystatin once a day; G.glabra L, glycyrrhiza glabra L; DMSO, dimethyl sulfoxide; NPs, Nanoparticle; PLA, polylactic acid; PLGA, polylactic-co-glycolic acid; MIC, Minimum inhibition concentration; C.Z, cinnamomun zeylanicum; C.V cinnamomum verum bark; PBS, Phosphate buffered saline.

## **Introduction**

*Candida Albicans* (*c.albicans*), is the most predominant species found in oral candidiasis, belongs to healthy flora in the oral cavity of human (1-3). It can convert into opportunistic pathogens due to predisposing factors such as poor oral hygiene, denture instability, systemic factors like immunologic and endocrine disease, medication such as steroids, broad-spectrum antibiotics, immunosuppressors, and various nutritional deficiencies (4). Some pathogenic mechanism in *c.albicans* transformation phases includes epithelial adherence, production of hydrolytic enzymes, biofilm formation, phenotypic changes, and morphogenesis (5, 6). Some of the clinical signs of oral candidiasis are thrush and creamy white crude like patches (2, 7).

The typical type of chronic oral candidiasis is denture stomatitis, and *c.albicans* is identified as the most crucial organism in this situation (8). Some factors, such as poor oral health, instability, loosening of denture, irregularity, and pore of the inner surface of denture, which is considered as a reservoir of microorganism, are attribute to the predisposing factors (8, 9). Furthermore, in severely compromised HIV patients, oropharyngeal candidiasis is prevalent, and *c.albicans* is the most common pathogen that is isolated from clinical specimens (10). Difficulty in chewing and swallowing can occur if untreated and can lead to weight loss (7).

Conventional synthetic drugs such as imidazole related compounds (e.g. miconazole, fluconazole) or polyenic derivatives (e.g. nystatin) are used for the treatment of candidiasis (4). However, drawbacks of these medications include the development of resistant strains or side effects such as bitter taste, allergic reaction, and adrenal insufficiency have necessitated a further search for alternative agents (5, 8).

In this context, herbs and naturally derived bioactive compounds become a new source of antimycotic therapy. Herbal medicine has antioxidants, anti-inflammatory, and antimicrobial properties due to their phytochemical constituents such as flavonoid and alkaloid (2, 11). Several reviews have indicated that herbal medicine and natural bioactive compounds have antibacterial, antiviral and antifungal effects (12-16). Thus, it is hypothesized that these natural products might have a beneficial effect on oral fungal flora such as *c.albicans*. Although the effects of herbs have been investigated as antifungal agents in several studies, to the best of our knowledge, the effects these natural products on *c.albicans* have not yet been reviewed. Thus, the aim of this study was to review the anti-candida activities of (especially against *Candida Albicans*) of herbal medicines and natural bioactive compounds. The methods and findings of reviewed studies are summarized in Table 1 to 4.

### ***Garlic***

Garlic (*Allium sativum*) is one of the herbal medicines with antimicrobial properties, which improves the functioning of the immune system (8). Garlic contains large amounts of organosulfur compounds, such as allicin and flavonoids, which may prevent oxidative damage and reduce blood pressure and hypercholesterolemia, which might lead to the reduction and

prevention of cardiovascular diseases (CVDs) and certain types of cancers (17, 18). In addition to several health benefits of garlic on chronic diseases, it is revealed that active components of garlic, allicin, and allietin (the most sulfur-containing compounds) have a therapeutic and antimicrobial properties (7). Allicin and garlic extract causes an increase in the synthesis of cytokines, macrophage activity, lymphocytes, and other cells of the immune system (8). It is effective against gram-positive and gram-negative bacteria, as well as *C. albicans* (7). Chemical reaction with thiol groups of various enzymes is the significant antimicrobial effect of allicin (8). Besides, the absorption of allicin and allietin through the digestive system and their further entrance in serum and blood could prevent the growth of micro-organisms (8). Two native South African garlic species are *Tulbaghia alliacea* and *Tulbaghia violacea*, which are traditionally used as remedies for a variety of infections and diseases (10). Regarding the antibacterial properties of garlic, several previous studies have assessed its impact on oral health, particularly *C. albicans*, the main findings of them are reviewed here.

In a randomized, double-blind clinical study, 40 aged people, who wear dentures, were divided into two groups. They were assigned to use garlic aqueous solution at a concentration of 40mg/ml three times a day for four weeks and compared with a control group, in which nystatin mouthwash (medication used to fight fungal infections of the mouth) was used instead of the garlic. Results revealed that the application of nystatin and garlic produced a significant effect on the length and width of erythema. However, garlic aqueous had fewer side effects in comparison with nystatin, so the authors concluded that garlic might be considered as an appropriate replacement for nystatin in handling denture stomatitis (8).

In another randomized clinical trial, 74 patients aged above 18 years were divided into two groups. One group was assigned to use garlic paste (quantity sufficient to cover the entire lesion) with one drop of 2% lignocaine jelly for four times a day for two weeks. Another group was asked to use 1% clotrimazole solution. Eighteen patients (7- clotrimazole, 11 garlic paste) did not turn up for clinical evaluation. Results of 56 patients showed that in all, 61.5% of the garlic group showed complete suppression of the lesion compared with 50% of the clotrimazole group. The two treatments did not show statistically significant differences in the response rate (19).

In an *in vitro* study, solvent extractions of different concentrations (0.06%, 0.15%, 0.30%) of *Tulbaghia alliacea* and *Tulbaghia violacea* and *Allium sativum* were prepared, using a solvent of water, methanol, and chloroform. All solutions were tested for antifungal activity against *Candida-Albicans* using agar plate disk. Results showed that extracts of *Tulbaghia violacea* were weakest in inhibiting the growth of *Candida*. *Tulbaghia alliacea* and *Allium sativum* aqueous extracts, at 0.15% and 0.30% concentrations, *T. alliacea* exhibited a more significant zone of inhibition than *A. sativum*. In methanol extracts at all concentrations, *T. alliacea* had a broader area of inhibition. In chloroform extracts, in 0.30% concentration, the most significant zone belonged to the *T. alliacea* (10). In an *in vitro* study, which studied traditional plants for managing candidiasis, they prepared plant material in an aqueous extract with 100 mg/ml

concentration. Then added extracts to sabouraud dextrose agar, which contain *Candida Albicans*. The aqueous extracts were divided into three parts stored at 4, 23, 33 °C for seven days to assay antifungal activity. Plants extracts of *Allium sativum* and *Tulbaghia violacea* had the best activity against *Candida Albicans*. *Allium sativum* and *Tulbaghia violacea* remained active for 3 and 2 days, respectively, when stored at 4°C. The *Allium sativum* extracts were the most stable in solution, although this activity decreased with longer storage (7) In an *in vitro* study, a total of 56 patients aged more than 40 years with acrylic dentures, who wore them at least six months, were included. The internal surface of denture was brushed with a sterile swab. Then swabs were suspended and prepared on CHROMagar candida at 36°C for two days and subsequently another additional seven days in  $30 \pm 1$  °C to ensure reducing false-negative results. The essential oil of *A.sativum* with a final concentration of 7.8 to 1000 µg/ml was used in this study. The control group was fluconazole with a level of 0.5 to 128 µg/ml. The results of this study shown that the essential oil of *A.sativum* is more effective than fluconazole in the prevention of the growth of both planktonic and biofilm of *Candida Albicans* extracts from dentures (5).

### **Green tea**

Green tea is one of the most popular beverages, which has a high amount of flavonoids with antioxidant properties. Catechins which constitute about 20% of green tea flavonoids are the major constitution of green tea. In addition to several health benefits of green tea and catechins including anti-hypertensive (20), hypolipidemic (21, 22), anti-hyperglycemic (23, 24), anti-arteriosclerotic (25), anti-cancer (26), antioxidant (27), and anti-thrombotic properties (28, 29), green tea (*Camellia Sinensis*) contains some polyphenolic ingredients which show antifungal activities against *Candida* species (30, 31). The potential antimicrobial properties of green tea are getting more prominent in recent decades (32).

Due to anti-inflammatory, antioxidant, anti-mutation, and anti-diabetic properties of green tea, it has an essential role in the improvement of erythema and mucosal inflammation (32). Green tea contains catechin, which is consist of epicatechin (EC) epigallocatechin (EGC), EC gallate, and EGC gallate (EGCG). EGEC and EGC can influence the proliferation of lymphocyte T and cytokines production; thus, it can be assumed that green tea and its extracts (such as flavonoid) possess immunomodulatory effects against oral candidiasis. Flavonoids can induce synthesis of IL8, IL17, which are chemoattractants resources and can recruit neutrophil for phagocytosis to impede *c.albicans* colony formation (1). Due to the antifungal activity of green tea, several studies have investigated the potential clinical applications of green tea on the oral cavity (33).

In a randomized clinical study, 22 patients with denture stomatitis were divided into two groups, namely nystatin and green tea. *Candida* infections of dentures were proved by culturing on CHROMagae candida medium; then patients received nystatin suspension 1000 µ/ml and 15 ml green tea mouthwash (0.5%) four times a day. Then lesion size was measured in 1st, 7<sup>th</sup>, and 14<sup>th</sup> days. The results showed that the mean of candida colonies showed significant differences in green tea and nystatin groups before and after treatment. The average length and width of the

lesion in these two groups decreased with the duration of treatment, and there were no statistically significant differences between nystatin and green tea (32). In an animal study, which was conducted on three months old Wistar rats, monoclonal antibodies (IL8, IL17, HBD-2) were analyzed. Immunocompromised rats (induced by dexamethasone 0.8 mg/kg and tetracycline 12 mg/kg intraperitoneally for seven days) were divided into seven groups: a control group and the group treated with green tea concentration of 1.25%, EGCG 1%, and EGC 1% for 4 and 7 days separately. Results showed that the expression of IL8, IL17, and HBD2 significantly increased in 7 days relative to 4 days. The expression of antibodies was considerably higher in green tea extracts group compared with EGC and EGCG. Also, there were insignificant differences between the EGC and EGCG groups (1). In an *in vitro* study, oral candida samples were collected from dental patients, and after preparation on CHROMagar medium, different concentrations of EGCG and different combination of EGCG and fluconazole or ketoconazole were prepared and added to the well after which incubated for 48 hours. The effect of EGCG with or without antifungal drugs was measured in this study to assess the synergistic effect of herbal and chemical drugs. The result was in the following order: EGCG alone showed a significant inhibitory effect on the growth of the colony. It was indicated that the mature biofilms of candida were resistant to fluconazole and ketoconazole. When EGCGA was combined with these drugs, the synergistic effect was observed in the inhibitory effect against Candida species (34). In another *in vitro* study, the effect of aqueous green tea was compared with free alcoholic mouthwash (Listerine) was analyzed. In this study, 60 specimens of heat-cured (HC) and microwaved cured (MV) acrylic resin were tested. The samples were treated with sabouraud broth and incubated for 24 hours in a vertical position due to biofilm formation. After this time, they were immersed in the mouthwash or green tea extract for 15 min. CFU was measured, and results revealed that in HC group, green tea reduced colony formation significantly compared with the control group but in MW group, green tea decreased non-significantly the colony count. In both groups, mouthwash has a significant inhibitory effect on colony formation (35).

## **Propolis**

Propolis is produced by honey bees from substances extracted from parts of some plants, buds and sap (36). With regard to a wide range of biological constituents (more than 230 constituents), propolis as a natural resin has several biological activities, including antioxidant, anti-inflammatory, antibacterial, antiviral, fungicidal, hepatoprotective, free radical scavenging, immunomodulatory and anti-diabetic activity (37, 38). For a long time, propolis was used to improve the health status of numerous diseases, such as mucocutaneous infections of fungal, bacterial and viral etiology and gastrointestinal disorders (39-41). Along with the antifungal activity of propolis, there is a hypothesis that it may cause a change in the phenotype of the fungus without reducing it quantitatively (4, 6). Because of this feature of propolis, several investigators have studied the antifungal action of propolis against Candida Albicans (42).

In a multicentric randomized trial, two groups of volunteers, with 20 patients per group, received treatment for denture stomatitis. The control group was treated with an oral gel containing 20 mg/g miconazole and propolis group used a gel with EPP-AP 2%. The treatment follows three times a day for 14 days. The results showed that a significant remission of the lesion during two weeks of treatment, and both groups achieved a 70% clinical cure rate. The CFU/ml count was reduced in the miconazole group, but the propolis group, besides its clinical improvement, did not show a significant reduction in the number of colonies (6).

In a randomized clinical trial, 45 patients, who were divided into three groups, were examined because of their denture stomatitis. One group received topical use of miconazole gel 2%, another one, propolis gel 2.5%, and the last one, propolis 24% in the form of mouthwash. The treatment lasts for two weeks, and four daily applications were used in these groups. The results presented that there were no statistical differences in efficacy among groups, and clinical remission of stomatitis, wholly or partially, was observed at the end of the treatment (4).

In a clinical pilot study, 30 patients were assigned to use a swab to dry the infected area beneath their complete denture and then apply drugs topically four times a day for seven days. One group (n=15) asked to use miconazole gel, and another group was allocated propolis gel. At the end of the week, no significant differences were observed among the two groups. All patients showed complete remission of palatal edema and erythema (43). In another clinical trial, 18 patients (6 patients in the control group) accept the treatment. In the control group, they were asked to use the solution of nystatin 100,000 UI/ML four times a day for one week. In the other group, they were asked to apply EEP 20% in the same way as used in control one. The results exhibited that all patients treated with EEP and antifungal drugs showed remission of the candidiasis lesions (44).

In an *in vitro/in vivo* study, antifungal activity of propolis was measured. First in the *in vitro* part, candida species were collected from dental school patients and cultured in M20 agar for 24 hours. Then, 1 to 10 mg/ml of propolis was added to the agar plate and incubated for 48, 72,96, and 120 hours at 37°C. Results showed that *c.albicans* was the most sensitive strain to propolis at 8 mg/ml concentration. In *in vivo* part, 12 patients, who wear a full denture and show stomatitis, were recruited to the study, five patients received hydroalcoholic solution 6% without propolis twice daily for two weeks. The rest of them received the hydroalcoholic solution of propolis (6%) in the form of mouthwash in the same way. Results revealed that all the patients in the propolis group show a significant reduction in the amount of candida in their saliva. However, the control group did not show any differences before and after treatment (45).

In an *in vitro* study, EEP3 and EEP13 were examined. Candida species were obtained from the bank of microorganisms. 0.2 to 500 µg/ml concentration of EEP was added to the medium and incubated at 35°C for 24 hours. The control group was nystatin. In this study, the observation was in the following order: both extracts have vigorous antifungal activity, and EEP13 was stronger than EEP3 (46). In another *in vitro* study, the effect of EEP on HIV-seropositive and

HIV-seronegative with oral candida was evaluated. *C.albicans* were obtained from 12 HIV-positive and 12 normal patients. After culturing candida, EEP 20% applied to the agar surface and incubated at 37°C for 48 hours. The results were compared with the Econazole (25mg), Clotrimazole (50mg) and Fluconazole (25mg). Also, 100 IU nystatin and 20 µl sterile distilled water were used as the positive and negative control group, respectively. The results were in the following order: in seronegative patients with denture stomatitis, *Candida Albicans* showed significant vulnerability to all antifungal and EEP groups. In the seropositive group, clotrimazole and fluconazole did not inhibit the growth of candida. Econazole was ineffective against fungus and EEP, and nystatin, with no significant differences between them, produced a bigger inhibition zone against candida. *Candida* was significantly susceptible to EEP and nystatin (42).

In another *in vitro* study, Egyptian propolis was assigned to assessed adhesion and germ tube formation of oral candida. *Candida* species were taken from a patient with acute pseudomembranous and cultured in YPD agar plate. EEP 5% with concentration 25 to 125 ng/µl added to agar plate and colonies were counted after 24 and 48 hours at 37°C. Results showed that a gradual decrease in CFU occurred at 75 ng/µl, and propolis was successful in preventing germ tube formation (47). In a review article that analyses phytomedicines for candida-associated denture stomatitis, pointed out that propolis may activate macrophage. Also, it is indicated that gel formulation could be used as an alternative topical choice for the improvement of denture stomatitis (48).

## **Curcumin**

Photodynamic therapy (PDT) originates in the interaction between two items: a nontoxic photosensitizer (PS) and visible light. Interaction between these two factors releases reactive oxygen species (ROS) in front of oxygen. ROS are toxic and can destroy microorganisms (49). Curcumin has excellent potential as a PS due to its ability to be activated by blue light (50). Also, curcumin possesses antitumor, anti-inflammatory, antioxidant, and antimicrobial features (16, 49). Regardless of these features, curcumin is lipophilic, so the clinical application of curcumin can be problematic. Numerous research performed to find out a more effective drug delivery system (51) and its potency as a PS, in addition to efficacy against oral candidiasis (52). In a single-center randomized clinical trial, thirty patients over 20 years old, who wears removable acrylic dentures and possess denture stomatitis, were divided into three groups. 1) Chitosan-curcuminoid (CHI- curcumin) mouthwash 0.1%, 2) chlorhexidine (CHX) mouthwash, and 3) vehicle formulation comprising chitosan 0.5% and PEG 400 (CHI). They were assigned to use them for 30 seconds three times a day for 14 days. Results showed that all groups had a high site activity in comparison with before treatment. CHI-curcumin was significantly stronger than other groups, which showed an 80% complete response (52). In an animal study, which considered photodynamic inactivation of *c.albicans* in a murine model, 45 mice were divided into different groups. The groups are in the following order: one negative control group that contains five mice without any immunosuppression and one positive control group that treated only with sterile



saline solution at 10% DMSO. Other groups received 7.4 (20  $\mu\text{M}$ ), 14.7 (40  $\mu\text{M}$ ), 29.5 (80  $\mu\text{M}$ ), mg/l of curcumin with and without LED (455nm, 89.2 MW/cm<sup>2</sup>). The last group received an LED light in the absence of curcumin. First of all, in treated groups, curcumin was topically applied to the dorsum of the tongue in a dark room for 20 minutes and was not swallowed. Then LED was performed for seven minutes. The results exhibited that PDT was effective against candida, and all concentrations of curcumin produce a significant reduction in colonies. However, there were trivial differences between 40 and 80  $\mu\text{M}$  (53). In another animal study, PDT by curcumin encapsulated in nanoparticles (curcumin-NPS) was conducted on the murine model, which were immunosuppressed to induce oral candidiasis. Two hundred thirty-five mice were selected in this study. Arrangement of groups was in the following order: the control group that received no treatment, free curcumin with and without PDT, anionic CUR-NP with and without PDT, cationic curcumin-NP with and without PDT. Nystatin (four times a day (NYS4) and once a day (Nys1)). The maximum concentration of curcumin was 260  $\mu\text{M}$ , and treatment was given daily for five days. Results revealed that free curcumin without light and anionic CUR-NP (with and without light) did not show a significant reduction in colonies, whereas other groups decreased colony counts. Free curcumin with PDT was similar to cationic curcumin. There were no differences between NYS1 and NYS4. There were no differences between cationic CUR-NP with or without PDT (51).

In another animal study that analyzes the effect of curcumin on oropharyngeal candidiasis, 35 of BALB/c mice were divided into five groups. Group I received 1 mg/kg dexamethasone, group II has gotten 200 mg/kg curcumin dissolved in 2% carboxymethyl cellulose orally, group III received dexamethasone plus curcumin and group IV and V has gotten saline. Induction of candidiasis and asthma was not performed on group V and the treatment lasted for five days. Outcomes showed that groups II and III showed a significant reduction in candidiasis without differences between them. Also, group I indicated a significant lessening, but it was lower than other groups (54).

In the *in vitro/ex vivo* study, the antifungal potential of curcumin was assessed; in the *ex-vivo* part, retention of curcumin in the mucosa was measured. Experiments were carried out with curcumin, and formulation diluted to 30% with artificial saliva. Results compared to the control group (curcumin dissolved in oleic acid). Outcomes showed that retention values after 12 hours in curcumin and formulation 30% were five times and three times higher than control, respectively suggesting that this system can be used for drug delivery. In the *in vitro* part, curcumin with concentration from 7.8 to 1000  $\mu\text{g/ml}$  was added to the well and incubated at 37°C for 48 hours. Control groups were amphotericin B (16  $\mu\text{g/ml}$ ) and fluconazole (512  $\mu\text{g/ml}$ ). Results revealed that curcumin was more effective than control groups against candida colonies (55).

In the *in vitro/in vivo* study, the efficacy of chitosan-curcumin was evaluated. The *in vivo* study was carried on hamsters and evaluated ulcer healing, which is not the purpose of this review.

Nevertheless, in the *in vitro* study, for determination against fungus in biofilm, 0.1% curcumin 0.5% chitosan mouthwash was used and compared to 0.2% CHX, blank formulation, formulation with 0.5% chitosan only and 0.1% curcumin only. Disks contain candida were soaked in these solutions for 10 minutes and then incubated for 24 hours at 37°C. Results revealed that when curcumin combined with chitosan, its anti-candida efficacy was comparable to CHX mouthwash (56). In another *in vitro* study, to assess PDT, an aqueous extract of curcumin 10.2% and methylene blue at 0.1% and 0.2% concentrations were used. Each solution measured with and without PDT and compared to the positive and negative control group, which was a culture without using PS and culture without *Candida Albicans*, respectively. As well, one group consist of 0.1ml nystatin was compared. The highest antifungal activity was observed in 10.2% curcumin with 460 nm diode laser (25 MW) for 30 s. furthermore, curcumin was significantly more efficient than nystatin (49). Recently, a review article determined the effectiveness of PDT on curcumin against several microorganisms and concluded that permanent DNA damage in candida occurred due to PDT. However, further investigations are needed in this aspect (50).

### **Licorice root**

Licorice root is composed of flavonoids and triterpenoids (57). Some bioactive natural compound in licorice root is glycyrrhiza species, glabridin, liquiritin (a glycosidic form of liquiritigenin) and lichochalcone A (11, 57, 58). These extracts show some antiinflammatory, antiulcer, antimicrobial, and antifungal activities (11). The effectiveness of licorice root in oral diseases such as dental caries, candidiasis, periodontal disease has been great interest recently (59). Several studies investigated the effect of licorice root on preventing and treating oral disease (59).

In a study that evaluates the antifungal activity of lichochalcone A against candidiasis, *in vitro* and *in vivo* studies were conducted. In the *in vitro* assay, commercial *Candida Albicans* strains and some resistant strain to fluconazole were selected. The final concentration of lichochalcone A was 2.8 to 280µM and used as a test group. Fluconazole (32-320µM) and nystatin (100 mM) used as positive control and 1% v/v ethanol as vehicle control. The drugs were applied to plates of candida and incubated for 24 hours at 37°C. Results demonstrated that in ordinary candida, lichochalcone A shows a comparable antifungal activity in similar potency of antifungal drugs, and in resistant strain, lower concentration of lichochalcone A was required to inhibit the growth of strain (60)

In the *in vivo* part of this study, 15 Balb/c mice were used. They were infected with oral candidiasis. The topical use of lichochalcone A (7.5 mM) for 30s was applied twice daily for five days. Nystatin (100 mM) and ethanol 1% used as positive control and vehicle control, respectively. Mice were euthanized, and the tongue of them was sectioned and evaluated. There was a significant reduction of strains in the lichochalcone A and nystatin group. The tongue of these samples showed less severity of hyphal invasion compare to the vehicle control (39).

In an *in vitro* study, the effect of different herbal drugs such as glycyrrhiza glabra L (G.glabra L) was assessed against candida and bacterial strains. Strains were cultured, and extracts of G.glabra L (0.19 to 100 mg/ml) were applied on plates and incubated for 24 hours at 37°C and was compared to untreated control culture. It showed that the highest cytotoxicity was related to G.glabra L in contrast to other herbal extracts, and candida species were more sensitive to the extracts than bacterial one (61).

In a further *in vitro* study, bioadhesive nanoformulation of G.glabra L was measured. Different solvents, nanoparticles, and mucoadhesives dosage form were used that are named in the following order: solutions such as ethanol/acetone/dimethyl sulfoxide (DMSO)/water and hydroalcoholic. Nanoparticles (NPS) such as alginate, polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), and NPS that were embedded into toothpaste, oral gel, and oral film. The final concentration of extracts was 10 mg/ml. They were applied on plates of c-albicans and incubated for 24 hours at 37°C. The results were compared with negative control (DMSO) and two positive ones (nystatin and free glabridin). The outcomes from this study showed that the most active extracts were ethanolic one (18% w/w). NPS was produced successfully, and the antifungal activity of NPS was similar to free extracts of glabridin in MIC. Also, the oral film with PLGA NPs showed the highest interaction with the mucin. Besides, toothpaste with alginate NPs and oral gel with PLA NPs show high interaction with mucin (11).

In another *in vitro* study, different types of G.glabra extracts were examined including leaf ethanolic (5.4%), leaf aqueous (4%), root ethanolic (10%) and root aqueous (9.6%). They were added on c-albicans agar plates in 4 and 8 mg/disk and incubated for 24 hours at 37°C. The outcomes were compared to chloramphenicol (30µg) and solvent disk as the positive and negative control, respectively. Results showed that leaf extracts exhibited better activity than root extracts. As well, ethanolic extracts showed the most antifungal activity (62). Moreover, an *in vitro* study, which examined antifungal activity of different medicinal plants, showed that extract of G.glabra L had a stronger inhibitory effect against other extracts. In comparison to antifungal agents, G.glabra L had better antifungal activity than fluconazole (10mcg) and itraconazole (10mcg) but lesser efficacy than clotrimazole (10mcg) that was not significant statistically. In their method, they applied extracts (50 g powder dissolved in 67% ethanol) of different plants on plates of c-albicans and incubated for 24-48-72 hours. G.glabra L showed maximum efficacy at all the time and was the most effective agent among all plants in this study (58). In a review article in 2018, they reviewed some articles such as Messier et al. (2011) (63), Utsunomiya et al. (2000) (64), Lee et al. (2009) (57) Fatima et al. (2009) (65), Kim j joo et al. (2013) (66) and concluded that licorice is a therapeutic agent and can be used as a substitute agent for oral candidiasis (59).

## **Cinnamon**

It has been shown that cinnamon possesses antiseptic, antimicrobial, analgesic properties (9). This feature, especially antifungal activity, may be related to cinnamaldehyde. It inhibits amino

acid decarboxylase activity. Cinnamaldehyde makes 50.5% of cinnamon bark and can involve in the biologic process due to its electronegative feature and reacts with the nitrogen-containing compound. This process inhibits the growth of microorganisms (67). According to these characteristics, several studies have been conducted to displayed numerous beneficial of cinnamon against fungus like candida-albicans. In a study comprising of *in vitro* and *in vivo* assay, essential oil of Cinnamomum zeylanicum (C.Z) against oral candidosis was evaluated. In phase I study (*in vitro*), essential oil at a concentration of 2 ppm used as a solvent and compared to nystatin (control). Oil added to plates of candida and incubated for 24 hours at 30°C. In part II (*in vitro*), thirty HC acrylic resins were divided into three groups of artificial saliva (negative control) mouthwash, C.Z and nystatin. The acrylic resin was immersed for 1 min, three times a day for 15 days. Finally in phase III (clinical) 15 patients who showed signs and symptoms of denture stomatitis, assigned to use mouthwash (C.Z) 3 times a day for about 60s in 15 days. Additionally, they received a container containing 500 ml of mouthwash to clean dental prostheses (9). Results of these three phases were in the following order: all the test strains showed sensitivity to essential oil, and c-albicans showed the most sensitive behavior. For acrylic resin, the surface hardness of prosthesis was analyzed, and the mouthwash group causes a lower degree of changes in hardness when compared with the nystatin group. Finally, the clinical phase of the study revealed that using mouthwash at a concentration of 635 µg/ml can heal the signs and symptoms (9). In another study, the effect of Cassia (Cinnamomum cassia) on the murine model and culture of c-albicans was evaluated, In the *in vitro* condition, the effect of different herbs was measured, and cinnamon, DMSO (as control) were compared, too. They were added to the well and incubated for 18 h at 37°C. Results showed that the inhibitory activity of cassia preparation was relatively stronger than other herbs. In the animal part of the study, 31 mice were examined for the cassia effect and 70 mice for other herbs. Cassia prepared in different concentrations 5% 25% and 100% (200 mg/ml). Control mice received no treatment. This preparation was administered by force-feeding. Results exhibited that 100% concentration showed a great clinical score in the tongue, whereas 5 and 25% did not (68). Furthermore, in an *in vitro* study. 100% (10 mg/ml) concentration of different extracts such as cinnamon was added to the standard strain of c-albicans and allowed to stand for 10 min, then incubated for 24 h at 37°C. the control group was DMSO. Results showed that cinnamon extract showed the highest antifungal activity in comparison with other herbs such as cumin, dried black pepper, dried India bay leaves (67). In an additional study that examined on antifungal activity of cinnamon bark and adherence to epithelial cells, they used cinnamon oil (1.25 to 0.195%), cinnulin pf (62,5-1000 µg/ml) as test group and nystatin was used as a reference. Summary of the results is in the following order: cinnamon oil showed inhibition of c.albicans growth, but cinnulin pf did not have any effect on fungus even at maximum concentration. However, both of them significantly reduced biofilm formation. Also, either of them (cinnulin more than cinnamon oil) reinforcing the epithelial could prevent the invasion of the oral mucosa by oral pathogens. Cinnulin pf meaningfully weakened the adherence of c.albicans while no such effect was observed with cinnamon oil. In conclusion, to obtain the best way against the adherence of candida and

inhibition of its growth is to combine two cinnamon fraction (69). In another *in vitro* study, at first, 7.8 to 1000 µg/ml concentration of cinnamon citronella essential oil was compared to nystatin and fluconazole (concentration range of 0.5-65 µg/ml). Agents were added to the *c.albicans* culture and incubated for 24-48 hours at 37°C. Secondly, 27 HC acrylic resins were contaminated with human saliva that was collected from two healthy people, and different considerations were performed to allow adherence of candida to the surface of acrylic resins. Three groups of acrylic resin immersed in PBS (control), cinnamon essential oil, and citronella essential oil for 3 min. The results of two parts of the study exhibited that both of the essential oil had an antifungal and antibiofilm activity that can be due to the lipophilic nature of essential oil that disrupts the cell membrane of microorganisms (70).

Moreover, in the *in vitro* study, the activity of Indian medical plants such as *Cinnamomum verum* bark (C.V) against fluconazole-resistant *Candida Albicans* was assessed. 250, 500 and 1000 µg/ml concentration of plants were prepared and added to the well and incubated for 24 h at 37°C. The results showed that all extracts, specially C.V, exhibited antimycotic activity and can be used as an alternative drug against *c.albicans* (2). Finally, another *in vitro* study that investigated the effect of different essential oil against microorganisms discovered the antibacterial and antifungal activity of all essential oil include cinnamon oil. Similarly, it showed that the largest active zone was attributed to cinnamon oil. In this study, their control group was olive oil, industrial paraffin oil, ethanol (70%) H<sub>2</sub>O<sub>2</sub> (3%) CHX (0.1%), and povidone-iodine. Also, their incubation time was 18h at 37°C (66).

### **Resveratrol**

Resveratrol is a major bioactive component in plant extracts that have been used for treating various human diseases as traditional medicine (71). Some pharmacological effects of resveratrol, such as antiviral, anti-inflammatory, lifespan extension, have been demonstrated in various studies. But little evidence about antifungal activity exists (72). In an *in vitro* study, 20-200 µg/ml stock solution of resveratrol was added to the well of *c.albicans* and incubated for 16h at 30°C. To assessed the morphological transition of *c.albicans*, they recognized that resveratrol was effective in both types of fungus (hyphal growth and yeast-form growth) and can inhibit *c.albicans* growth. Also, resveratrol impaired morphological transition in various situations. For instance, serum induction, nutrient starvation, and neutral ph. They mentioned that the inhibition of yeast form occurred at 100 or 200 µg/ml concentration (72). Moreover, another *in vitro* study has been indicated that the compound of resveratrol can disrupt the serum-induced filamentous form of *c.albicans*. They stated that potential antifungal activity was at 10-20 µg/ml concentration. Nevertheless, it was a little less potent than amphotericin B that used as a control group. They proposed that the antifungal activity of resveratrol is due to the induction of some intracellular physiological changes, Trehalose accumulation happens, and cell-cycle will be arrested (71). On the contrary, an *in vitro* study that used 0.2, 2, and 20 µg/ml solution of resveratrol and compared with fluconazole (0-0.128 µg/ml) stated that no distinct reaction

observed against *C. albicans* even at 20 µg/ml. They incubated the plates with resveratrol and *Candida* for 24 h at 37°C. In their study, different experimental conditions and types of *Candida* strains were mentioned as a variable effect of resveratrol's antifungal properties (73). On the other hand, the latest study in 2019, which investigates the antibiofilm activity of a semi-synthetic molecule obtained from resveratrol, showed antifungal activity of this phytochemical. In this study, 0.81 to 20.31 mM concentration of EB487 (resveratrol) was applied to the well and incubated at 37 for 24 h. They concluded that above 8.13 mM would inhibit biofilm growth regardless of the studied strains and 20.32 mM as the highest tested concentration inhibits 80% biofilm growth (74).

## Ginger

Ginger is used to treating movement disorders, nausea, and vomiting during pregnancy in traditional medicine (75). It consists of polyphenol compounds in its root and extract, which have considerable antioxidant activity. Several studies have shown antibiofilm activity against pathogenic bacteria (76) and antifungal properties against *C. albicans* isolated from the patient with genital candidiasis. However, there are only a few studies evaluating the effect of ginger on oral candidiasis (75). In an *in vitro* study, the mouthwash form of ginger was applied to the well of *Candida* and incubated for 24 h. Different concentrations of ginger (0.625 to 80 mg/ml) were compared to Muller-Hinton agar without ginger extracts and 70% ethanol as control groups. They concluded that biofilm reduction started at a concentration of 0.625 mg/ml, and at 40 mg/ml, no sign of biofilm formation was observed. Indeed, they mentioned that 0.625 to 5 mg/ml could be used successfully against *Candida* colonization in the oral cavity (75). In another *in vitro* study, the effect of essential oils of different plants such as cinnamon, ginger rhizome, rosemary, thyme, sage, and basil against *C. albicans* was investigated. *C. albicans* was selected from HIV-positive patients infected by oropharyngeal candidiasis or immunocompromised patients with disseminated fungal infection. Also, commercial strains were used in this study as control strains. *Candida* species were divided into two groups: fluconazole-susceptible and fluconazole-resistant (76). The essential oil was prepared with 50 to 3200 µg/ml concentrations applied to the well and incubated for 48 h at 35°C. Results showed that ginger essential oil exhibited significant antifungal activity against both groups of *Candida*, but its potency was the lowest in comparison with cinnamon or oregano and thyme. They stated that the fluconazole-resistant group was more susceptible to this essential oil (76). Moreover, a further *in vitro* study evaluated different components of ginger: three gingerols (6-gingerol, 8-gingerol, 10-gingerol) and three shogaols (6-shogaol, 8-shogaol, 10-shogaol) against fluconazole-resistant *C. albicans*. They used DMSO 0.1% as the control group, and the concentration of extracts was 0-500 µg/ml. Their outcome was in the following order: 6-gingerol, 8-gingerol, and 6-shogaol demonstrated antibiofilm activity at levels 10, 50, 100 µg/ml, while 10-gingerol, 8-shogaol, and 10-shogaol showed no effect even at 100 µg/ml. In reality, they concluded that the antibiofilm activity of the compound was attributed to the number of carbon side chains, as carbon side chain numbers become weighty, antibiofilm activity appeared to decrease (77).

## **Berberine**

Berberine is identified as a defense compound in plants and protects them against microorganisms (78). Some pharmacological effects of berberine are recognized, such as antiarrhythmic, anti-inflammatory and anticancer properties (79). Several studies assessed the pharmacology and clinical efficacy of berberine and have suggested its antimicrobial, antifungal, and antiviral effects (78). In an *in vitro* study, the effects of berberine alone and in combination with fluconazole and miconazole were investigated. They used 1.95 to 250 mg/l for berberine, 0.125 to 4 mg/l for miconazole, and 0.5 to 16 mg/l for fluconazole and added to the plate of candida species and incubated for 24 hours at 37°C. Results revealed that berberine showed antifungal activity against candida species, but non-albicans strains were more vulnerable than *C. albicans*. Also, they stated that berberine plus miconazole or fluconazole showed a strong synergic effect against both forms of *C. albicans* (planktonic and biofilm) (78). In another *in vitro* study, the potential effect of berberine alone and in combination with fluconazole were analyzed against fluconazole-resistant *C. albicans*. 0.125 to 64 µg/ml of fluconazole and 1 to 32 µg/ml of berberine were used, and outcomes demonstrated that berberine and fluconazole alone had a weak antifungal activity. In contrast, a combination of these substances produced a large and significant inhibition zone in *C. albicans* plates (80). In another *in vitro* study, the sensitization of *C. albicans* to terbinafine by BBR and berberrubine were analyzed. They applied 100 µg/ml of materials in the plates and incubated for 48 h at 35°C. Their results revealed that berberine and berberrubine (it is analog) alone showed small or no antifungal activity, but the combination of 100 µg berberine and 6 µg terbinafine showed significant antifungal activity, even when compared with terbinafine alone. They stated that berberine, in conjunction with terbinafine, does not show any inhibition zone on the well (81). In contrast, an *in vitro* study showed that BBR might enter *C. albicans* cell and act in both extracellular and intracellular sites. BBR treatment will decrease ergosterol, so it leads to the loss of membrane permeability and cause the cell death of *C. albicans*. They assessed 5, 10, 25, 50 and 100 µg/ml of berberine and added to the well and compared them with PBS. They incubated at 37°C for 15 and 60 min. They concluded that berberine accumulation at a dose of 50 µg/ml is time-dependent and suggested that berberine may serve as an alternative treatment for candidiasis (82). Furthermore, a further *in vitro* study demonstrated that after 24 hours of treatment with berberine, mitochondrial dysfunction was observed in fluconazole-resistant *C. albicans* strains. They stated that BBR prompts the apoptotic mechanism in fungus, which are resistant to fluconazole. In their study, they examined 0.125 to 64 µg/ml of concentration of berberine against *C. albicans*, and incubation time lasts for 24 h at 35°C. They showed that berberine reduced the number of *C. albicans* in all level due to induction of instability in the cell membrane of fluconazole-resistant strains (83).

## **Conclusion and future perspective**

This review has comprehensively assessed the effects of nutraceuticals and other diet ingredients on *Candida Albicans* in oral candidiasis based on pre-clinical and clinical trials. The results have

shown that almost all of the nutraceuticals and specific diet ingredients discussed above such as garlic, green tea, propolis, curcumin, licorice root, cinnamon, resveratrol, ginger, and berberine are useful in the treatment of *Candida Albicans* in oral candidiasis. These nutraceuticals are not expensive without any major side effects compared to other pharmacological agents. However, most of the evidence was based on the *in vitro* situation and animal studies, so it is strongly recommended to conduct more clinical trials to show the effectiveness of these phytochemicals on humans as well as the optimum dose and duration of treatment.



## References

1. Rahayu RP, Prasetyo RA, Purwanto DA, Kresnoadi U, Iskandar RPD, Rubianto M. The immunomodulatory effect of green tea (*Camellia sinensis*) leaves extract on immunocompromised Wistar rats infected by *Candida albicans*. *Vet World*. 2018;11(6):765-70.
2. Varadarajan S, Narasimhan M, Malaisamy M, Duraipandian C. Invitro Anti-mycotic Activity of Hydro Alcoholic Extracts of Some Indian Medicinal Plants against Fluconazole Resistant *Candida albicans*. *J Clin Diagn Res*. 2015;9(8):Zc07-10.
3. Rautemaa R, Ramage G. Oral candidosis--clinical challenges of a biofilm disease. *Crit Rev Microbiol*. 2011;37(4):328-36.
4. Capistrano HM, de Assis EM, Leal RM, Alvarez-Leite ME, Brener S, Bastos EM. Brazilian green propolis compared to miconazole gel in the treatment of *Candida*-associated denture stomatitis. *Evid Based Complement Alternat Med*. 2013;2013:947980.
5. Mendoza-Juache A, Aranda-Romo S, Bermeo-Escalona JR, Gomez-Hernandez A, Pozos-Guillen A, Sanchez-Vargas LO. The essential oil of *Allium sativum* as an alternative agent against *Candida* isolated from dental prostheses. *Rev Iberoam Micol*. 2017;34(3):158-64.
6. Pina GM, Lia EN, Berretta AA, Nascimento AP, Torres EC, Buszinski AF, et al. Efficacy of Propolis on the Denture Stomatitis Treatment in Older Adults: A Multicentric Randomized Trial. *Evid Based Complement Alternat Med*. 2017;2017:8971746.
7. Motsei ML, Lindsey KL, van Staden J, Jager AK. Screening of traditionally used South African plants for antifungal activity against *Candida albicans*. *J Ethnopharmacol*. 2003;86(2-3):235-41.
8. Bakhshi M, Taheri JB, Shabestari SB, Tanik A, Pahlevan R. Comparison of therapeutic effect of aqueous extract of garlic and nystatin mouthwash in denture stomatitis. *Gerodontology*. 2012;29(2):e680-4.
9. Oliveira Jde A, da Silva IC, Trindade LA, Lima EO, Carlo HL, Cavalcanti AL, et al. Safety and Tolerability of Essential Oil from *Cinnamomum zeylanicum* Blume Leaves with Action on Oral Candidosis and Its Effect on the Physical Properties of the Acrylic Resin. *Evid Based Complement Alternat Med*. 2014;2014:325670.
10. Thamburan S, Klaasen J, Mabusela WT, Cannon JF, Folk W, Johnson Q. *Tulbaghia alliacea* phytotherapy: a potential anti-infective remedy for candidiasis. *Phytother Res*. 2006;20(10):844-50.
11. Roque L, Duarte N, Bronze MR, Garcia C, Alopaeus J, Molpeceres J, et al. Development of a bioadhesive nanoformulation with *Glycyrrhiza glabra* L. extract against *Candida albicans*. *Biofouling*. 2018;34(8):880-92.
12. Pavithra P, Janani V, Charumathi K, Indumathy R, Potala S, Verma RS. Antibacterial activity of plants used in Indian herbal medicine. *International Journal of Green Pharmacy (IJGP)*. 2010;4(1).
13. Erdogrul ÖT. Antibacterial activities of some plant extracts used in folk medicine. *Pharmaceutical Biology*. 2002;40(4):269-73.
14. Martin KW, Ernst E. Herbal medicines for treatment of fungal infections: a systematic review of controlled clinical trials. *Mycoses*. 2004;47(3-4):87-92.
15. Shahidi Bonjar G, Aghighi S, Karimi Nik A. Antibacterial and antifungal survey in plants used in indigenous herbal-medicine of south east regions of Iran. *Journal of Biological Sciences*. 2004;4(3):405-12.
16. Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. *BioMed research international*. 2014;2014.
17. Borek C. Antioxidant health effects of aged garlic extract. *The Journal of nutrition*. 2001;131(3):1010S-5S.

18. Tsai C-W, Chen H-W, Sheen L-Y, Lii C-K. Garlic: Health benefits and actions. *BioMedicine*. 2012;2(1):17-29.
19. Sabitha P, Adhikari PM, Shenoy SM, Kamath A, John R, Prabhu MV, et al. Efficacy of garlic paste in oral candidiasis. *Trop Doct*. 2005;35(2):99-100.
20. Kim J-a, Formoso G, Li Y, Potenza MA, Marasciulo FL, Montagnani M, et al. Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn. *Journal of Biological Chemistry*. 2007;282(18):13736-45.
21. Murase T, Haramizu S, Shimotoyodome A, Tokimitsu I, Hase T. Green tea extract improves running endurance in mice by stimulating lipid utilization during exercise. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*. 2006;290(6):R1550-R6.
22. Koo SI, Noh SK. Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. *The Journal of nutritional biochemistry*. 2007;18(3):179-83.
23. Ueda M, Nishiumi S, Nagayasu H, Fukuda I, Yoshida K-i, Ashida H. Epigallocatechin gallate promotes GLUT4 translocation in skeletal muscle. *Biochemical and biophysical research communications*. 2008;377(1):286-90.
24. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. *Journal of the American College of Nutrition*. 2007;26(4):373S-88S.
25. Sakata R, Nakamura T, Torimura T, Ueno T, Sata M. Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: a double-blind placebo-controlled study. *International journal of molecular medicine*. 2013;32(5):989-94.
26. Khan N, Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. *Cancer letters*. 2008;269(2):269-80.
27. Hakim IA, Harris RB, Brown S, Chow HS, Wiseman S, Agarwal S, et al. Effect of increased tea consumption on oxidative DNA damage among smokers: a randomized controlled study. *The Journal of nutrition*. 2003;133(10):3303S-9S.
28. Stangl V, Lorenz M, Stangl K. The role of tea and tea flavonoids in cardiovascular health. *Molecular nutrition & food research*. 2006;50(2):218-28.
29. Bagherniya M, Nobili V, Blesso CN, Sahebkar A. Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review. *Pharmacological research*. 2018;130:213-40.
30. Camargo LE, Pedroso LS, Vendrame SC, Mainardes RM, Khalil NM. Antioxidant and antifungal activities of *Camellia sinensis* (L.) Kuntze leaves obtained by different forms of production. *Brazilian journal of biology = Revista brasleira de biologia*. 2016;76(2):428-34.
31. Aladag H, Ercisli S, Yesil DZ, Gormez A, Yesil M. Antifungal activity of green tea leaves (*Camellia sinensis* L.) sampled in different harvest time. *Pharmacognosy Magazine*. 2009;5(20):437.
32. Ghorbani A, Sadrzadeh A, Habibi E, Dadgar K, Akbari J, Moosazadeh M, et al. Efficacy of *Camellia sinensis* extract against *Candida* species in patients with denture stomatitis. *Curr Med Mycol*. 2018;4(3):15-8.
33. Tamura M, Saito H, Kikuchi K, Ishigami T, Toyama Y, Takami M, et al. Antimicrobial activity of Gel-entrapped catechins toward oral microorganisms. *Biol Pharm Bull*. 2011;34(5):638-43.
34. Behbehani JM, Irshad M, Shreaz S, Karched M. Synergistic effects of tea polyphenol epigallocatechin 3-O-gallate and azole drugs against oral *Candida* isolates. *J Mycol Med*. 2019;29(2):158-67.
35. Antunes DP, Salvia AC, de Araujo RM, Di Nicolo R, Koga Ito CY, de Araujo MA. Effect of green tea extract and mouthwash without alcohol on *Candida albicans* biofilm on acrylic resin. *Gerodontology*. 2015;32(4):291-5.

36. Sanghani NN, Shivaprasad B, Savita S. Health from the hive: propolis as an adjuvant in the treatment of chronic periodontitis-a clinicomicrobiologic study. *Journal of clinical and diagnostic research: JCDR*. 2014;8(9):ZC41.
37. Armutcu F, Akyol S, Ustunsoy S, Turan FF. Therapeutic potential of caffeic acid phenethyl ester and its anti-inflammatory and immunomodulatory effects. *Experimental and therapeutic medicine*. 2015;9(5):1582-8.
38. Zhu W, Chen M, Shou Q, Li Y, Hu F. Biological activities of Chinese propolis and Brazilian propolis on streptozotocin-induced type 1 diabetes mellitus in rats. *Evidence-Based Complementary and Alternative Medicine*. 2011;2011.
39. Nolkemper S, Reichling J, Sensch KH, Schnitzler P. Mechanism of herpes simplex virus type 2 suppression by propolis extracts. *Phytomedicine*. 2010;17(2):132-8.
40. Coelho L, Bastos E, Resende CC, Sanches B, Moretzsohn L, Vieira W, et al. Brazilian green propolis on *Helicobacter pylori* infection. a pilot clinical study. *Helicobacter*. 2007;12(5):572-4.
41. Santos V, Pimenta F, Aguiar M, Do Carmo M, Naves M, Mesquita R. Oral candidiasis treatment with Brazilian ethanol propolis extract. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*. 2005;19(7):652-4.
42. Martins RS, Pereira ES, Jr., Lima SM, Senna MI, Mesquita RA, Santos VR. Effect of commercial ethanol propolis extract on the in vitro growth of *Candida albicans* collected from HIV-seropositive and HIV-seronegative Brazilian patients with oral candidiasis. *J Oral Sci*. 2002;44(1):41-8.
43. Santos VR, Gomes RT, de Mesquita RA, de Moura MD, Franca EC, de Aguiar EG, et al. Efficacy of Brazilian propolis gel for the management of denture stomatitis: a pilot study. *Phytother Res*. 2008;22(11):1544-7.
44. Santos VR, Pimenta FJ, Aguiar MC, do Carmo MA, Naves MD, Mesquita RA. Oral candidiasis treatment with Brazilian ethanol propolis extract. *Phytother Res*. 2005;19(7):652-4.
45. Ota C, Unterkircher C, Fantinato V, Shimizu MT. Antifungal activity of propolis on different species of *Candida*. *Mycoses*. 2001;44(9-10):375-8.
46. Freires IA, Queiroz V, Furletti VF, Ikegaki M, de Alencar SM, Duarte MCT, et al. Chemical composition and antifungal potential of Brazilian propolis against *Candida* spp. *J Mycol Med*. 2016;26(2):122-32.
47. Gomaa OM, Gaweesh AS. Variation in adhesion and germ tube formation of oral *Candida* using Egyptian propolis. *Can J Microbiol*. 2013;59(3):197-203.
48. Casaroto AR, Lara VS. Phytomedicines for *Candida*-associated denture stomatitis. *Fitoterapia*. 2010;81(5):323-8.
49. Daliri F, Azizi A, Goudarzi M, Lawaf S, Rahimi A. In vitro comparison of the effect of photodynamic therapy with curcumin and methylene blue on *Candida albicans* colonies. *Photodiagnosis Photodyn Ther*. 2019;26:193-8.
50. Santezi C, Reina BD, Dovigo LN. Curcumin-mediated Photodynamic Therapy for the treatment of oral infections-A review. *Photodiagnosis Photodyn Ther*. 2018;21:409-15.
51. Sakima VT, Barbugli PA, Cerri PS, Chorilli M, Carmello JC, Pavarina AC, et al. Antimicrobial Photodynamic Therapy Mediated by Curcumin-Loaded Polymeric Nanoparticles in a Murine Model of Oral Candidiasis. *Molecules*. 2018;23(8).
52. Mustafa MW, Ungphaiboon S, Phadoongsombut N, Pangsomboon K, Chelae S, Mahattanadul S. Effectiveness of an Alcohol-Free Chitosan-Curcuminoid Mouthwash Compared with Chlorhexidine Mouthwash in Denture Stomatitis Treatment: A Randomized Trial. *J Altern Complement Med*. 2019;25(5):552-8.

53. Dovigo LN, Carmello JC, de Souza Costa CA, Vergani CE, Brunetti IL, Bagnato VS, et al. Curcumin-mediated photodynamic inactivation of *Candida albicans* in a murine model of oral candidiasis. *Med Mycol.* 2013;51(3):243-51.
54. Karaman M, Arikan Ayyildiz Z, Firinci F, Kiray M, Bagriyanik A, Yilmaz O, et al. Effects of curcumin on lung histopathology and fungal burden in a mouse model of chronic asthma and oropharyngeal candidiasis. *Arch Med Res.* 2011;42(2):79-87.
55. Fonseca-Santos B, Bonifacio BV, Baub TM, Gremiao MPD, Chorilli M. In-Situ Gelling Liquid Crystal Mucoadhesive Vehicle for Curcumin Buccal Administration and Its Potential Application in the Treatment of Oral Candidiasis. *J Biomed Nanotechnol.* 2019;15(6):1334-44.
56. Mahattanadul S, Mustafa MW, Kuadkaew S, Pattharachayakul S, Ungphaiboon S, Sawanyawisuth K. Oral ulcer healing and anti-*Candida* efficacy of an alcohol-free chitosan-curcumin mouthwash. *Eur Rev Med Pharmacol Sci.* 2018;22(20):7020-3.
57. Lee JY, Lee JH, Park JH, Kim SY, Choi JY, Lee SH, et al. Liquiritigenin, a licorice flavonoid, helps mice resist disseminated candidiasis due to *Candida albicans* by Th1 immune response, whereas liquiritin, its glycoside form, does not. *Int Immunopharmacol.* 2009;9(5):632-8.
58. Sharma H, Yunus GY, Agrawal R, Kalra M, Verma S, Bhattar S. Antifungal efficacy of three medicinal plants *Glycyrrhiza glabra*, *Ficus religiosa*, and *Plantago major* against oral *Candida albicans*: A comparative analysis. *Indian J Dent Res.* 2016;27(4):433-6.
59. Sidhu P, Shankargouda S, Rath A, Hesarghatta Ramamurthy P, Fernandes B, Kumar Singh A. Therapeutic benefits of liquorice in dentistry. *J Ayurveda Integr Med.* 2018.
60. Seleem D, Benso B, Noguti J, Pardi V, Murata RM. In Vitro and In Vivo Antifungal Activity of Licochalcone-A against *Candida albicans* Biofilms. *PLoS One.* 2016;11(6):e0157188.
61. de Oliveira JR, de Castro VC, das Gracias Figueiredo Vilela P, Camargo SE, Carvalho CA, Jorge AO, et al. Cytotoxicity of Brazilian plant extracts against oral microorganisms of interest to dentistry. *BMC Complement Altern Med.* 2013;13:208.
62. Irani M, Sarmadi M, Bernard F, Ebrahimi Pour GH, Shaker Bazarnov H. Leaves Antimicrobial Activity of *Glycyrrhiza glabra* L. *Iran J Pharm Res.* 2010;9(4):425-8.
63. Messier C, Grenier D. Effect of licorice compounds licochalcone A, glabridin and glycyrrhizic acid on growth and virulence properties of *Candida albicans*. *Mycoses.* 2011;54(6):e801-6.
64. Utsunomiya T, Kobayashi M, Ito M, Pollard RB, Suzuki F. Glycyrrhizin improves the resistance of MAIDS mice to opportunistic infection of *Candida albicans* through the modulation of MAIDS-associated type 2 T cell responses. *Clin Immunol.* 2000;95(2):145-55.
65. Fatima A, Gupta VK, Luqman S, Negi AS, Kumar JK, Shanker K, et al. Antifungal activity of *Glycyrrhiza glabra* extracts and its active constituent glabridin. *Phytother Res.* 2009;23(8):1190-3.
66. Warnke PH, Becker ST, Podschun R, Sivananthan S, Springer IN, Russo PA, et al. The battle against multi-resistant strains: Renaissance of antimicrobial essential oils as a promising force to fight hospital-acquired infections. *J Craniomaxillofac Surg.* 2009;37(7):392-7.
67. Latti P, Ramanarayanan S, Prashant GM. Antifungal Efficacy of Spice Extracts against *Candida albicans*: An in vitro study. *Indian J Community Med.* 2019;44(Suppl 1):S77-s80.
68. Taguchi Y, Takizawa T, Ishibashi H, Sagawa T, Arai R, Inoue S, et al. Therapeutic effects on murine oral candidiasis by oral administration of cassia (*Cinnamomum cassia*) preparation. *Nihon Ishinkin Gakkai Zasshi.* 2010;51(1):13-21.
69. Veilleux MP, Grenier D. Determination of the effects of cinnamon bark fractions on *Candida albicans* and oral epithelial cells. *BMC Complement Altern Med.* 2019;19(1):303.
70. Almeida Lde F, Paula JF, Almeida RV, Williams DW, Hebling J, Cavalcanti YW. Efficacy of citronella and cinnamon essential oils on *Candida albicans* biofilms. *Acta Odontol Scand.* 2016;74(5):393-8.

71. Jung HJ, Seu YB, Lee DG. Candidicidal action of resveratrol isolated from grapes on human pathogenic yeast *C. albicans*. *J Microbiol Biotechnol*. 2007;17(8):1324-9.
72. Okamoto-Shibayama K, Sato Y, Azuma T. Resveratrol impaired the morphological transition of *Candida albicans* under various hyphae-inducing conditions. *J Microbiol Biotechnol*. 2010;20(5):942-5.
73. Weber K, Schulz B, Ruhnke M. Resveratrol and its antifungal activity against *Candida* species. *Mycoses*. 2011;54(1):30-3.
74. Juin C, Perrin F, Puy T, Bernard C, Mollichella ML, Girardot M, et al. Anti-biofilm activity of a semi-synthetic molecule obtained from resveratrol against *Candida albicans* biofilm. *Med Mycol*. 2019.
75. Aghazadeh M, Zahedi Bialvaei A, Aghazadeh M, Kabiri F, Saliani N, Yousefi M, et al. Survey of the Antibiofilm and Antimicrobial Effects of *Zingiber officinale* (in Vitro Study). *Jundishapur J Microbiol*. 2016;9(2):e30167.
76. Pozzatti P, Scheid LA, Spader TB, Atayde ML, Santurio JM, Alves SH. In vitro activity of essential oils extracted from plants used as spices against fluconazole-resistant and fluconazole-susceptible *Candida* spp. *Can J Microbiol*. 2008;54(11):950-6.
77. Lee JH, Kim YG, Choi P, Ham J, Park JG, Lee J. Antibiofilm and Antivirulence Activities of 6-Gingerol and 6-Shogaol Against *Candida albicans* Due to Hyphal Inhibition. *Front Cell Infect Microbiol*. 2018;8:299.
78. Wei GX, Xu X, Wu CD. In vitro synergism between berberine and miconazole against planktonic and biofilm *Candida* cultures. *Arch Oral Biol*. 2011;56(6):565-72.
79. Iwazaki RS, Endo EH, Ueda-Nakamura T, Nakamura CV, Garcia LB, Filho BP. In vitro antifungal activity of the berberine and its synergism with fluconazole. *Antonie Van Leeuwenhoek*. 2010;97(2):201-5.
80. Quan H, Cao YY, Xu Z, Zhao JX, Gao PH, Qin XF, et al. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of *Candida albicans* resistant to fluconazole. *Antimicrob Agents Chemother*. 2006;50(3):1096-9.
81. Lam P, Kok SH, Lee KK, Lam KH, Hau DK, Wong WY, et al. Sensitization of *Candida albicans* to terbinafine by berberine and berberrubine. *Biomed Rep*. 2016;4(4):449-52.
82. Zoric N, Kosalec I, Tomic S, Bobnjarić I, Jug M, Vlajnić T, et al. Membrane of *Candida albicans* as a target of berberine. *BMC Complement Altern Med*. 2017;17(1):268.
83. da Silva AR, de Andrade Neto JB, da Silva CR, Campos Rde S, Costa Silva RA, Freitas DD, et al. Berberine Antifungal Activity in Fluconazole-Resistant Pathogenic Yeasts: Action Mechanism Evaluated by Flow Cytometry and Biofilm Growth Inhibition in *Candida* spp. *Antimicrob Agents Chemother*. 2016;60(6):3551-7.



**Table 1. The effects of nutraceuticals and herbal medicine on *Candida Albicans* based on *in vitro* studies**

<i>Author, Year</i>	<i>Type of article</i>	<i>Agent</i>	<i>concentration</i>	<i>Way of candida collection</i>	<i>Treatment duration</i>	<i>Intervention assigned to the control group</i>	<i>Type of application</i>	<i>Main outcome</i>
Thamburan et al. 2006 (10)	In vitro	Tulbaghia alliacea Tulbaghia violacea Allium sativum	0.06% 0.15% 0.30%	The culture was obtained from the university	24 hours	Fluconazole drug	Aqueous Methanol chloroform	Extracts of T.violacea were most inferior in preventing the growth of the fungus; they were inactive at the lowest concentration of 0.06% and only shown small zones of inhibition at the higher concentrations. In contrast, all extracts of T.alliacea at all concentrations exhibited antifungal activity
Motsei et al., 2003 (7)	In vitro	Tulbaghia violacea Allium sativum Other species	100 mg/ml	From 5-month-old baby and patient in Christ The King hospital	7 days	Amphotericin B	Aqueous	They had the best activity against candida-Albicans
Mendoza-Juache et al.	In vitro	Allium sativum	7.8 to 1000 µg/ml	56 patients who wear the	48 hours	fluconazole	Essential oil	the essential oil of A.sativum is more effective than

2017 (5)				denture				fluconazole
Behbehani et al. 2019 (34)	In vitro	EGCG	0.98 to 62,5 µg/ml	Collected from dental patient	48 hours	Fluconazole and ketoconazole	solution	The synergistic effect of EGCG was supported in this study. EGCG alone can inhibit the growth of candida in planktonic and biofilm mode.
Antunes et al, 2015 (35)	In vitro	Green tea extract	10 ml	Acrylic resin	24 hours	Distilled water	aqueous	Green tea was significantly effective in the heat-cured group but not in microwave one.
Ota et al, 2001 (45)	In vitro/in vivo	Brazilian propolis	1-10 mg	Dental school patient	48, 72, 96, 120 hours	ethanol	solution	Candida Albicans was most sensitive strain to propolis, especially at 8 mg/ml
Freires et al. 2016 (46)	In vitro	Brazilian propolis (EEP3, EEP13)	0.2 TO 500 µg/ml	Bank of microorganism	24 hours	nystatin	liquid	Strong antifungal activity was observed, and EEP 13 has a lower MIC than EEP3
Martins et al. 2002 (42)	In vitro	Brazilian propolis (EEP 20%)	20 µl	12 HIV-seropositive and seronegative patient	48 hours	Nystatin(100 IU) Distilled water(20µl) Fluconazole(25mg) Clotrimazole(50 mg) Econazol(25mg)	Solution	In seropositive patient: EEP and nystatin was effective against candida and candida was resistant to other drugs In seronegative patient: candida was vulnerable to all antifungal drugs and EEP
Gomaa et al.	In vitro	Egyptian propolis (5%)	25 to 125 ng/µl	Patient with acute	24 and 48 hours	Culture control( no additional	solution	EEP was successful in preventing candida



2013 (47)				pseudomembranous disease		drug)		growth at 75 ng/μl
Fonseca santos et al. 2019 (55)	In vitro Ex-vivo	Curcumin	5 mg/g 7.8 to 1000 μg/ml	School of pharmaceutical sciences	12 hours 14 hours	Curcumin in oleic acid Fluconazole(512 μg/ml) Amphotericin B(16 μg/ml)	Solution	The formulation was effective in improvement of candidiasis  Curcumin was more potent than other groups
Mahattanadul et al.2018(56)	In vitro	Chitosan-curcumin	0.15	Bioprosthetic biofilm colonization model	10 minutes + 24 hours incubation time	CHX group 0.2 w/v 0.9% normal saline	mouthwash	Curcumin in addition to chitosan act as a safe agent to the management of candidiasis
Daliri et al. 2019 (49)	In vitro	Curcumin	10.2%	Did not mentioned	30, 60 , 120s PDT time and 24 hours incubation time	Positive control: culture without PS Negative control: culture without c-albicans nystatin	Aqueous extract	CUR 10.2% in 30 s has the highest antifungal activity
Seleem et al. 2016 (60)	In vitro/In vivo	Lichochalcone A (licorice root)	2.8-280 μM	Commercial strain ATCC 90028	24 hours	Fluconazole (32-320 μM) Nystatin (100 Mm) Ethanol 1%	solution	Antifungal activity of Lichochalcone A was comparable to antifungal drugs.
Oliveira et al. 2013	In vitro	G.glabra L (licorice root)	0.19 to 11 mg/ml	Obtained from the oral cavity	24 hours	Untreated group	solution	G.glabra L shows the highest cytotoxicity effect especially against

(61)				of pulmonary tuberculosis patient				candida albicans strain
Roque et al. 2018 (11)	In vitro	G.glabra L (licorice root)	10 mg/ml	Commercial strain ATCC 10231	24 hours	Nystatin Glabridin DMSO	Toothpaste Oral gel Oral film	Ethanol extracts showed the highest antifungal activity and oral film with PLGA exhibit the most interaction with mucin
Irani et al. 2010 (62)	In vitro	G.glabra L (licorice root)	4 and 8 mg/disk	Commercial strain ATCC 10231	24 hours	Chloramphenicol (30 µg) solvent	Ethanol aqueous	Leave extracts and ethanolic form had significant antifungal activity
Sharma et al. 2016 (58)	In vitro	G.glabra L (licorice root)	50 gr in 67% ethanol	Commercial strain ATCC 66027	24,48,72 hours	Fluconazol(10mcg) Itraconazol(10mcg) clotrimazol(10mcg)	solution	G.glabra L had greatest antifungal activity compared to fluconazole and itraconazole and insignificant activity in comparison with clotrimazole
Oliveira et al. 2014 (9)	In vitro/ in vivo	C.Z(cinnamon)	2ppm	Commercial strain ATCC 76485 30 HC acrylic resin	1: 24 hours 2: 15 days	2: artificial saliva Nystatin (100000 UI/ML)	1:ESSENTIAL OIL 2:mouthwash	Cinnamon inhibits the growth of c.albicans The hardness of acrylic resins in cinnamon mouthwash influenced less than nystatin group
Taguchi	Invitro/invi	Cassia(cinnam)	100% ( 0.2	Commercial	18 H	DMSO 10%	solution	Strongest effect was

et al. 2010(68 )	vo	on cassia)	mg/ml)	l strain TIMM1768				related to cinnamon
Latti et a. 2019(67 )	Invitro	cinnamon	100%(10 mg/ml)	Commercia l strain ATCC2091	24 h	DMSO	Crude extract solution	Cinnamon had maximum antifungal activity in comparison with other drugs
Veilleux et al, 2019(69 )	Invitro	Cinnamon Cinnulin pf	1.25-0.195 % 62.5 to 1000 µg/ml	Commercia l strain ATCC28366 And cases of systemic candidiasis	24 h	nystatin	Essential oil	Cinnamon oil in combination with cinnulin of can act as an antifungal agent and prevent adhesion of candida to the oral mucosa
Almeida et al. 2016 (70)	In vitro	Cinnamon citronella	1:7.8 to 1000 µg/ml 2:1 mg/ml	1:Commerc ial strain ATCC90028 and 2:Human saliva	1:24-48 h 2:immersio n for 3 min and incubation for 24 h	1:Nystatin(0.5 to 64 µg/ml) and fluconazole 2:PBS	Essential oil	Both essential oils exhibited antifungal and antibiofilm activity
Warnke et al. 2009 (66)	In vitro	cinnamon	Did not mentioned	Commercia l strain ATCC10231	18 h	Olive oil Industrial paraffin oil Ethanol 70% H2O2 3% CHX 0.15 Povidone-iodine	Essential oil	The largest effective zone belongs to cinnamon oil.
Lam et al, 2016 (81)	In vitro	Berberine berberrubine	100 µg/ml	Obtain from the American type of	48 h	Terbinafine DMSO	solution	BBR in combination with terbinafine will produce larger inhibition zone in plates of c.albicans. but

				culture collection				BBR or berberrubine alone did not inhibit the growth of c.albicans
Wei et al. 2011 (78)	In vitro	Berberine	1.95 to 250 mg/l	Obtained from the college of dentistry	24 hours	Fluconazole(0.5 to 16 mg/l) Miconazole (0.125 to 4 mg/l)	solution	A combination of BBR and miconazole or fluconazole showed strong antifungal activity. However, BBR showed antifungal activity alone.
Quan et al. 2006 (80)	In vitro	Berberine	1 to 32 µg/ml	40 clinical isolated of fluconazole -resistant strains ATCC90028	24 H	ATCC90028 as the control group	solution	BBR or fluconazole do not show significant Antifungal activity, but the combination of them revealed strong antifungal properties
Zoric et al. 2017 (82)	In vitro	Berberine	5.10.25.50,100 µg/ml	ATCC90028	15 and 60 min	PBS	solution	BBR showed strong antifungal activity against c.albicans
Silva et al. 2016 (83)	In vitro	Berberine	0.125 to 64 µg/ml	Blood sample at central public health	24 h	Other strains of candida used as controls	solution	BBR showed great antifungal activities.
Aghazadeh et al. 2016 (75)	In vitro	Zingiber officinale(ginger)	0.625 to 80 mg/ml	Clinical isolate from the Iranian research organization	24h	No treatment in control Ethanol 70%	mouthwash	0.625 to 5 mg/ml can be used successfully in the oral cavity for antibiofilm activity against c.albicans.

				n				
Pozzatti et al. 2008 (76)	In vitro	Ginger rhizome	50 to 3200 µg/ml	ATCC0231 HIV positive with oropharyngeal candidiasis Immunocompromised with disseminated candidiasis ATCC90028	48 h	No additional treatment	solution	Ginger showed antifungal activity but it was not as potent as oregano, thyme, and cinnamon
Lee et al. 2018 (77)	In vitro	Ginger (gingerol, shogaol)	0-1000 µg/ml	DAY185	24 h	DMSO 0.1%	solution	Ginger showed that antifungal activity in compound contains a smaller carbon side chain
Okamoto-Shibayama et al. 2010 (72)	In vitro	resveratrol	20-200 µg/ml	SC5314	16h	No additional treatment	solution	Resveratrol is effective against the yeast form of c.albicans
Jung et al. 2007 (71)	In vitro	resveratrol	10-40 µg/ml	Center for academic societies in japan	48H	Amphotericin B	solution	Resveratrol had antifungal activity at a final concentration of 10-20 µg/ml

Weber et al. 2011 (73)	In vitro	Resveratrol(R 5010)	0.2-2-20 µg/ml	ATCC90028 ATCC76615 SC5314	24H	Fluconazole (0 to 128 µg/ml)	solution	Resveratrol did not inhibit candida's growth
Juin et al. 2019 (74)	In vitro	Resveratrol(E B487)	0.81 to 20.32 mM	Atcc28367 Ca14-p	24 h	Untreated group	solution	Strong ability of EB487 was demonstrated to inhibit biofilm growth and preformed biofilm

**Table 2. The effects of nutraceuticals and herbal medicine on Candida Albicans based on clinical trials**

<i>Author, Year</i>	<i>Type of article</i>	<i>Agent</i>	<i>Dose</i>	<i>Treatment duration</i>	<i>Number of participants</i>	<i>Mean age</i>	<i>Intervention assigned to the control group</i>	<i>Type of application</i>	<i>Main outcome</i>
Bakhshi, et al, 2012(8)	randomized double-blind clinical trial	garlic	40 mg/ml	4 weeks	40	73,52 ± 9.81	Nystatin mouthwash	Aqueous solution	Improving the erythematous lesion
Sabitha et al. 2005(19)	Randomized clinical trial	garlic	Quantity sufficient to cover entire lesion	2 weeks	56	More than 18	Clotrimazole solution 1%	paste	As effective as clotrimazole
Ghorbani et al, 2018(32)	Clinical trial	Camellia sinensis	0.5%	1 and 7 and 14 days	22	65±11.3	Nystatin suspension 1000 u/ml	mouthwash	Length and width of lesion decreased in green tea groups as well as nystatin
Pina et al,2017(6)	Multicentric randomized	Brazilian propolis	2%	2 weeks	40	Over 60 years	Miconazole 20mg/g	gel	EEP-AP seems to be no inferior

	d trial								to miconazole and can be recommended as an alternative
Capistrano et al, 2013(4)	Randomized clinical trial	Brazilian propolis	2% 24%	2 weeks	45	60.76±11.34	Miconazole gel 2%	Gel mouthwash	Both forms of propolis have antifungal activity similar to miconazole
Santos et al, 2008(43)	Clinical pilot study	Brazilian propolis	10%	1 week	30	51	miconazole	gel	Complete remission of the lesion in both groups was observed
Santos et al, 2005(44)	Clinical trial	Brazilian propolis	20%	1 week	18	42	Nystatin 100.000 UI/ML	Solution(bottle)	Propolis group treated lesion similar to control group
Ota et al, 2001(45)	Invitro/invivo	Brazilian propolis	6%	2 weeks	12	-	Hydroalcoholic without propolis	mouthwash	Propolis group showed a significant reduction in



									number of candida
Mustafa et al. 2019(52)	Single center RCT	curcumin	0.1%	2 weeks	30	58	CHX mouthwash Chitosan 0.5%	mouthwash	Efficacy of CHI-CUR mouthwash was better than other groups
Oliveira et al. 2014(9)	Invitro/in vivo	C.Z( cinnamon)	625 µg/ml	15 days	15	40-60 years	Compared to invitro part of the study	mouthwash	None of patients showed signs and symptoms anymore

**Table 3. The effects of nutraceuticals and herbal medicine on *Candida Albicans* based on animal studies**

<i>Author , Year</i>	<i>Animal type</i>	<i>Agent</i>	<i>Dose</i>	<i>Treatment duration</i>	<i>Number of animals</i>	<i>Intervention assigned to the control group</i>	<i>Type of assessment</i>	<i>Main outcome</i>
Rahayu et al, 2018 (1)	Wistar rats	Camellia sinensis	Green tea 1.25% EGCG 1% EGC 1%	4 and 7 days	35	No additional treatment	Collection of blood serums	Green tea has an immunomodulatory and positive effect against candida more than two other type
Dovigo et al. 2013 (53)	Murine model	curcumin	7.4 , 14.7 and 29.5 mg/ml	20 minutes preactivation time 7 minute LED	45	Positive: DMSO 10% Negative: animals without immunosuppression	Samples swabbed from the tongue of mice	All curcumin and LED light were able to create a significant reduction in colonies count
Sakima et al.2018 (51)	Murine model	curcumin	260 $\mu$ M	5 days	235	No additional treatment	Samples swabbed from the tongue of mice	Cationic CUR-NP $\pm$ PDT, NYS1, NYS4, and free CUR+ PDT shows good antifungal activity
Karaman et al, 2011(54)	BALB/c mice	curcumin	200 mg/kg	5 days	35	Negative control: without candida Positive control: saline solution	Serum sample were assessed	Curcumin in combination with dexamethasone shows significant reduction in

								candida colonies
Seleem et al. 2016 (60)	BALB/c mice	licorice	7.5 mM	5 days	15	Nystatin(100m M) ETHANOL 1%	After euthanizing the mice tongues were sectioned	Lichoalcone A and nystatin show significant antifungal activity
Taguchi et al. 2010 (68)	In vitro/in vivo	Cassia(cinnamon)	5% 25% 100%(200mg/ml)	5 times after infection (3,21,27,45, 41 hours)	101	No additional control group	Samples swabbed from tongue of mice	100% concentration exhibited antifungal activity and eradicated the symptom

**Table 4. Summary of review studies regarding the effects of nutraceuticals and herbal medicine on *Candida Albicans***

<b>Author, year</b>	<b>Type</b>	<b>Number of included studies</b>	<b>agent</b>	<b>Main outcome</b>
Casaroto et al. 2010 (48)	Review	3 in vitro 2 in vivo	propolis	Propolis can be suggested for the treatment of candidiasis
Santezi et al. 2018 (50)	Review	Total: 28 Candida-albicans: 7	curcumin	PDT promote a reduction of c-albicans
Sidhu et al. 2018 (59)	Review	3 animal 3 invitro	Licorice root	Licorice can be mentioned as a useful therapeutic agent and as an alternative drug for oral candidiasis.